Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma.

Of note, log 2 -fold changes in nivolumab independent PD-1 expression for those with clinical response (n = 3) was –1.42 versus –1.02 in those without clinical response (n = 8); a trend that did not reach statistical significance ( P = .15 by two-sided, unpaired T-test).

also in 111,027 other papers